The Latest Breaking News from Abbott Laboratories

Abbott Laboratories has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

Abbott Laboratories shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.

Abbott Laboratories is one of the best dividend stocks to buy today: here's why.

The medtech market is thriving, thanks to the increasing investments and surging demand for enhanced efficiency. Therefore, investors could benefit from these trends by investing in fundamentally solid medical device stocks Becton, Dickinson and Company (BDX), Medtronic (MDT), and Abbott Laboratories (ABT), which are revolutionizing patient care. Keep reading.

The healthcare industry is set for growth due to the growing demand for quality treatments and ongoing progress in medical technology. Hence, investors might consider investing in healthcare stocks, Eli Lilly (LLY), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) for a healthy portfolio in 2025. Read more….

Despite Abbott Laboratories’ underperformance relative to the broader Nasdaq Composite over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Despite Abbott Laboratories’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

The medical devices industry is on the verge of an incoming boom, fueled by its growing demand and technological advancements. In this evolving landscape, investors could scoop up shares of robust medical device stocks Alcon (ALC), Becton, Dickinson (BDX), and Abbott (ABT) for solid gains. Read more….

Abbott stock edged higher Wednesday after the health care giant narrowly beat Wall Street's third-quarter expectations.